Atara Biotherapeutics Q2 revenue falls on deferred revenue recognition
ATRA•Outlook and regulatory update
The company said operating expenses are expected to decline significantly year over year because of the cost-reduction initiatives.
Atara said its cash and investments are expected to fund operations into mid-2027. It also expects a further regulatory update on the tabelecleucel BLA resubmission later this quarter.
Losses narrow as operating costs drop
Atara reported a Q2 net loss of $4.83 million, or $0.32 per basic and diluted share.
Q2 operating income was -$4.72 million. Costs and operating expenses declined 87% year over year, driven by cost-reduction initiatives implemented in 2025 and the first half of 2026.
Q2 revenue falls despite beat on commercialization revenue
Atara Biotherapeutics said Q2 revenue beat analyst expectations but fell sharply year over year.
The company reported Q2 commercialization revenue of $630,000, compared with a consensus estimate of $366,670 from three analysts. Revenue declined mainly because of accelerated recognition of deferred revenue in 2025 after the transition of development activities to Pierre Fabre Laboratories.
